Polymeric Diet Alone Versus Corticosteroids in the Treatment of Active Pediatric Crohn’s Disease: A Randomized Controlled Open-Label Trial

Borrelli, Osvaldo; Cordischi, L.; Cirulli, M.; Paganelli, Massimiliano; Labalestra, V.; Uccini, Stefania; Russo, Paolo Maria; Cucchiara, Salvatore

doi:10.1016/j.cgh.2006.03.010

Cited by 404 publications

(411 citation statements)

References 44 publications

Supporting

Mentioning

381

Contrasting

Unclassified

Order By: Relevance

“…A recent prospective, 10-week open-label trial in children with active naive CD randomized children to orally polymeric formula alone or oral corticosteroids. In this small study, children with active and recently diagnosed CD, a short course of polymeric diet was more effective than corticosteroids in inducing healing of gut inflammatory lesions [27] . Further large scaled studies are needed to further evaluate the short and long term benefits of this treatment strategy.…”

Section: Treatmentmentioning

confidence: 69%

Special issues in pediatric inflammatory bowel disease

Dubinsky¹

2007

WJG

View full text Add to dashboard Cite

The incidence of pediatric inflammatory bowel disease (IBD) is rising and recent advances in diagnostics and therapeutics have improved the care provided to these children. There are distinguishing features worth noting between early onset and adult onset IBD. Physical and psychosocial development remains a critical target for the comprehensive management of pediatric IBD. Children are not just little adults and consideration must be given to the stages of development and how these stages impact disease presentation and management. The final stage will be the transition from pediatric care to that of adult oriented care and special consideration must be given to make this a successful process. This review highlights special considerations in the management of the child with IBD.

show abstract

Section: Treatmentmentioning

confidence: 69%

Special issues in pediatric inflammatory bowel disease

Dubinsky¹

2007

WJG

View full text Add to dashboard Cite

show abstract

“…Polymeric formulas have shown similar efficacy in comparison to elemental formulas [79] with inherent advantages including better palatability, reduction of the need for tube feeding and improved adherence [80]. In children, EEN was demonstrated to be as effective as corticosteroids in inducing remission [81][82][83] and was superior in inducing mucosal healing [84,85]. EEN downregulates pro-inflammatory cytokines including TNF-α and IL-6 [86,87], induces prompt reduction in inflammatory markers with a consequent increase in IGF-1 and IGFBP-3 within 14 days of treatment [85,88,89].…”

Section: Exclusive Enteral Nutrition (Een)mentioning

confidence: 99%

Impact of Therapeutic Strategies on Growth in Pediatric Inflammatory Bowel Disease

Shamir¹

2014

J Clin Cell Immunol

View full text Add to dashboard Cite

Growth retardation is a common complication of pediatric inflammatory bowel disease (IBD), which may have long term effects on final adult height and carries significant social and psychological implications. Etiology may be multifactorial including undernutrition, metabolic dysregulation, inflammatory impact on hormonal growth axis and the effect of drugs such as glucocorticoids. Control of disease activity and minimizing the need for corticosteroid therapy are necessary measures in order to facilitate normal growth. However, in many cases these strategies are not sufficient. Currently, there is inconsistent evidence regarding the efficacy of available therapeutic agents to induce long-term effect on growth. The new era of biologic therapies which carries a greater potential to achieve mucosal healing, holds promise for better growth even in children with severe growth impairment. It becomes apparent that prompt recognition of growth impairment combined with aggressive tailored therapeutic approach may offer the best chance for catch-up growth. This review will discuss the definition, prevalence and mechanism of growth retardation in children with IBD and highlight the specific benefits of current therapeutic strategies.

show abstract

“…EEN is one of the few current medical therapies recognized to promote high rates of MH. Borrelli et al reported that 74% of a group of 19 children managed with EEN had MH after a course of EEN [28]. This contrasts with a rate of 33% in a comparison group (n = 18) treated with corticosteroids to www.expert-reviews.com Review induce remission.…”

Section: Other Benefits Of Eenmentioning

confidence: 99%